Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Submission based on results from pivotal phase III trial showing all primary endpoints met
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated